Articles tagged with: Kyprolis
The annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) took place earlier this month. The two meetings were attended by tens of thousands of physicians from around the world, and featured a myriad of oral presentations, posters, and e-abstracts summarizing the results of new oncology- and hematology-related research.
Included in the research presented at the two meetings were more than 200 studies discussing new multiple myeloma-related findings.
In addition to the two large meetings held earlier this month, the International Myeloma Working …
A poster session yesterday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting was the venue for the first substantial dose of multiple myeloma-related presentations at the conference.
During the session, research results were made available for review by meeting attendees in the form of posters, each of which summarized the results of a single study. As is typically the case during such sessions, each poster was about two feet high by three or four feet in length. All posters were displayed throughout a large conference hall.
The 51st annual meeting of the American Society of Clinical Oncology (ASCO) started earlier today, May 29, and will go through June 2 in Chicago.
Approximately 30,000 physicians and researchers from all over the world are expected to attend the five-day meeting to discuss current research in cancer treatment and care.
During the meeting, there will be presentations about all types of cancer, including many presentations focused specifically on multiple myeloma. In fact, more than 90 myeloma-related studies are scheduled to be presented, in one form or another, in connection …
The results of a small Phase 1/2 clinical trial suggest that a combination of Farydak and high-dose Kyprolis is effective as a treatment for relapsed multiple myeloma.
Participants in the trial were heavily pretreated, having had a median of five previous myeloma therapies. More than 70 percent of the patients, however, had at least a partial response to the trial regimen at the target doses established during the trial’s first phase. The estimated two-year overall survival rate among the patients was 67 percent.
A response rate of more than 70 …
Erste Ergebnisse einer großen, direkten, klinischen Vergleichsstudie zeigen, dass rezidivierte Myelompatienten, die mit hochdosiertem Kyprolis und Dexamethason behandelt wurden, ein doppelt so langes progressionsfreies Überleben hatten im Vergleich zu rezidivierten Patienten, die mit Velcade und Dexamethason behandelt wurden.
Das mittlere progressionsfreie Überleben in der Phase 3-Studie betrug 18,7 Monate bei den mit hoch dosiertem Kyprolis (Carfilzomib) und Dexamethason behandelten Studienteilnehmern im Vergleich zu 9,4 Monaten bei Patienten, die Velcade (Bortezomib) und Dexamethason erhielten.
Die Ergebnisse der so genannten "ENDEAVOR"-Studie wurden am letzten Sonntagabend in einer von Amgen (NASDAQ:AMGN) herausgegebenen Presseinformation …